DRMA · Dermata Therapeutics, Inc.
$1.42
+0.04 (+2.90%)
At close · Aug 21
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”View the 10-Q filed Aug 11, 2026
Market Cap
$5.71M
Shares
4.02M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$7.56M
+38.5%
FY2025
Diluted EPS
-$8.16
+89.8%
FY2025
Operating Cash Flow
-$7.8M
+30.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $203.44K | — | — | — | $63.57K | -$45.61K | — | |
| $1.63M | $2.93M | $8.2M | $4.07M | $5.65M | $3.46M | $1.61M | |
| $4.05M | — | $4.31M | $3.97M | $4.02M | $4.4M | $1.57M | |
| $6.97M | $4.84M | $4.31M | — | — | — | — | |
| — | — | — | — | — | $0 | $322 | |
| $8.6M | $7.77M | $12.51M | $8.04M | $9.67M | — | — | |
| -$8.6M | -$7.77M | -$12.51M | -$8.04M | -$9.67M | -$7.86M | -$3.17M | |
| $655 | — | — | — | — | $45.61K | $197.27K | |
| $232.37K | $215.04K | $225.78K | — | — | — | — | |
| — | — | $0 | $0 | $0 | $0 | $0 | |
| -$8.37M | -$7.56M | -$12.29M | -$7.79M | -$9.61M | -$7.9M | -$3.24M | |
| — | — | — | — | -$9.61M | -$10.46M | -$3.24M | |
| — | — | — | — | $0 | $2.29M | — | |
| USD/shares | — | -$8.16 | -$80.32 | -$399.90 | -$2,088.00 | -$5,832.00 | -$4,056.00 |
| USD/shares | — | -$8.16 | -$80.32 | -$399.90 | — | — | — |
| shares | — | 926.19K | 152.97K | — | — | 1792.5967 | 796.2538 |
| shares | — | 926.19K | 152.97K | 19.49K | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.67×
EV/EBIT
—
Peer median 10.95×
P/E (TTM)
—
Peer medians compare against the 168 similar-size Biotechnology companies (of 545 listed).